Helicobacter pylori and Virulence Factors (VacA and CagA)
Infection with Helicobacter pylori is one of the most common worldwide, affecting a large share of the global population. This bacterium is associated with several gastrointestinal diseases, including chronic gastritis, peptic ulcer, and gastric cancer. Identifying not only the presence of the bacterium, but also its main virulence factors—such as the VacA and CagA toxins—is essential for clinical risk assessment and for defining the therapeutic approach.
Helicobacter pylori is a Gram-negative, microaerophilic, spiral-shaped bacterium adapted to survive in the acidic environment of the human stomach. Its ability to colonize the gastric mucosa is related to mechanisms such as urease production, flagellar motility, and expression of specific virulence factors.
Among the main factors associated with pathogenicity are:
VacA (Vacuolating cytotoxin A) – toxin that induces vacuole formation in epithelial cells, promoting cell damage and inflammation.
CagA (Cytotoxin-associated gene A) – protein associated with greater gastric inflammation, cellular changes, and increased risk of gastric cancer.
The presence of these genes is associated with more severe clinical presentations and a higher potential for complications.
Infection with H. pylori is usually acquired in childhood and may persist for life if untreated. Transmission occurs mainly via the oral–oral or fecal–oral route and is associated with poor sanitary conditions and high population density.
Prevalence is higher in developing countries and is considered an important public health problem due to its association with gastric neoplasms.
Most infected individuals may remain asymptomatic. However, in symptomatic cases, the following may occur:
Epigastric pain or discomfort
Nausea and vomiting
Feeling of gastric fullness
Chronic gastritis
Gastric or duodenal ulcer
Gastric adenocarcinoma
MALT lymphoma
Strains carrying the VacA and especially CagA genes are associated with greater inflammation, tissue damage, and increased risk of malignancy.
Diagnosis of H. pylori infection can be performed using invasive methods (biopsy with urease test, histology, culture) or noninvasive methods (urea breath test, stool antigen test, and molecular methods).
Real-Time PCR stands out for enabling:
Direct detection of bacterial DNA
High sensitivity and specificity
Simultaneous identification of virulence genes (VacA and CagA)
Fast and reliable results
Molecular identification of the VacA and CagA genes provides relevant prognostic information, supporting patient risk stratification.
Appropriate management of the infection includes:
Early diagnosis
Combination antimicrobial therapy
Eradication monitoring
Follow-up of patients at higher risk of complications
Identifying more virulent strains supports more individualized clinical decisions.
Infection with H. pylori is among the leading risk factors for gastric cancer, one of the most common neoplasms worldwide. The clinical impact involves costs for diagnosis, treatment, endoscopic follow-up, and management of complications.
Accurate, early detection, combined with identification of virulence factors, represents a significant advance in clinical management and in preventing severe outcomes.
The Bioperfectus Real-Time PCR Kit for Detection of Helicobacter pylori and Toxins (VacA/CagA) was developed to provide rapid, sensitive, and highly specific molecular diagnosis.
Simultaneous detection of H. pylori and the main virulence genes (VacA and CagA)
High diagnostic sensitivity, even at low bacterial loads
Fast results, optimizing clinical decision-making
Support for risk stratification, identifying potentially more aggressive strains
Improved therapeutic monitoring
By integrating the Bioperfectus Kit into the laboratory routine, clinics and hospitals expand diagnostic capacity, enable more precise interventions, and strengthen prevention of complications associated with H. pylori infection.
Real-Time PCR technology provides not only confirmation of infection, but also strategic information on the bacterial virulence profile, contributing to more personalized and effective medicine.
